Gamma-aminobutyric acid receptor subunit gamma-1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit gamma-1 as ChEMBL target CHEMBL296, mapped to UniProt P23574. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Gamma-aminobutyric acid receptor subunit gamma-1 matters
Gamma-aminobutyric acid receptor subunit gamma-1 is reviewed as Gamma-aminobutyric acid receptor subunit gamma-1 (UniProt P23574); the current evidence base includes 1 approved drug, 24 compounds, and 22 assays, with lead potency reaching pChEMBL 8.4.
Gamma-aminobutyric acid receptor subunit gamma-1 Sequence length is 465 aa.
Review this target as Gamma-aminobutyric acid receptor subunit gamma-1, mapped to UniProt P23574. Sequence length is 465 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 1 approved drug, 24 compounds, and 22 assays for this target. The dominant activity type is IC50. CHEMBL42464 is the current potency anchor at pChEMBL 8.4.
Use CHEMBL42464 as the tractability anchor when discussing potency (pChEMBL 8.4).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit gamma-1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P23574, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL42464
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL12
|
8.3 | IC50 | Approved |
|
|
No preferred name
CHEMBL273481
|
8.2 | IC50 | — |
|
|
No preferred name
CHEMBL10450
|
7.6 | IC50 | — |
|
|
No preferred name
CHEMBL96
|
7.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
DIAZEPAM
CHEMBL12
|
1963 |